Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hartmut Goldschmidt

Showing results (271-280 of 539) with videos related to

Pageof 54
Sort By:
Transplantation|November 16, 2005
Indications for high-dose chemotherapy with autologous stem cell support in patients with systemic amyloid light chain amyloidosisStefan O Schonland, Jolanta B Perz, Michael Hundemer, et al.
Haematologica|November 28, 2015
Concomitant gain of 1q21 and MYC translocation define a poor prognostic subgroup of hyperdiploid multiple myelomaNiels Weinhold, Desiree Kirn, Anja Seckinger, et al.
Frontiers in Oncology|November 11, 2021
Prevalence of the GFI1-36N SNP in Multiple Myeloma Patients and Its Impact on the PrognosisCyrus Khandanpour, Christine Eisfeld, Subbaiah Chary Nimmagadda, et al.
Transplantation|November 16, 2005
Risk stratification in cardiac amyloidosis: novel approachesArnt V Kristen, F Joachim Meyer, Jolanta B Perz, et al.
Cancers|September 10, 2020
Spatial Distribution of Focal Lesions in Whole-Body MRI and Influence of MRI Protocol on Staging in Patients with Smoldering Multiple Myeloma According to the New SLiM-CRAB-CriteriaMarkus Wennmann, Thomas Hielscher, Laurent Kintzelé, et al.
Haematologica|March 22, 2015
A magnetic resonance imaging-based prognostic scoring system to predict outcome in transplant-eligible patients with multiple myelomaElias K Mai, Thomas Hielscher, Jost K Kloth, et al.
Leukemia & Lymphoma|May 10, 2018
Propensity score matching analysis to evaluate the comparative effectiveness of daratumumab versus real-world standard of care therapies for patients with heavily pretreated and refractory multiple myelomaShaji Kumar, Brian Durie, Hareth Nahi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 20, 2008
Analysis of herpes zoster events among bortezomib-treated patients in the phase III APEX studyAsher Chanan-Khan, Pieter Sonneveld, Michael W Schuster, et al.
Blood Advances|November 12, 2021
MCT1 is a predictive marker for lenalidomide maintenance therapy in multiple myelomaJacob Stroh, Anja Seckinger, Michael Heider, et al.
Molecular Medicine (Cambridge, Mass.)|August 24, 2018
Enrichment of B cell receptor signaling and epidermal growth factor receptor pathways in monoclonal gammopathy of undetermined significance: a genome-wide genetic interaction studySubhayan Chattopadhyay, Hauke Thomsen, Miguel Inacio da Silva Filho, et al.
Pageof 54

Showing results (271-280 of 539) with videos related to

Sort By:
Pageof 54
Transplantation|November 16, 2005
Indications for high-dose chemotherapy with autologous stem cell support in patients with systemic amyloid light chain amyloidosisStefan O Schonland, Jolanta B Perz, Michael Hundemer, et al.
Haematologica|November 28, 2015
Concomitant gain of 1q21 and MYC translocation define a poor prognostic subgroup of hyperdiploid multiple myelomaNiels Weinhold, Desiree Kirn, Anja Seckinger, et al.
Frontiers in Oncology|November 11, 2021
Prevalence of the GFI1-36N SNP in Multiple Myeloma Patients and Its Impact on the PrognosisCyrus Khandanpour, Christine Eisfeld, Subbaiah Chary Nimmagadda, et al.
Transplantation|November 16, 2005
Risk stratification in cardiac amyloidosis: novel approachesArnt V Kristen, F Joachim Meyer, Jolanta B Perz, et al.
Cancers|September 10, 2020
Spatial Distribution of Focal Lesions in Whole-Body MRI and Influence of MRI Protocol on Staging in Patients with Smoldering Multiple Myeloma According to the New SLiM-CRAB-CriteriaMarkus Wennmann, Thomas Hielscher, Laurent Kintzelé, et al.
Haematologica|March 22, 2015
A magnetic resonance imaging-based prognostic scoring system to predict outcome in transplant-eligible patients with multiple myelomaElias K Mai, Thomas Hielscher, Jost K Kloth, et al.
Leukemia & Lymphoma|May 10, 2018
Propensity score matching analysis to evaluate the comparative effectiveness of daratumumab versus real-world standard of care therapies for patients with heavily pretreated and refractory multiple myelomaShaji Kumar, Brian Durie, Hareth Nahi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 20, 2008
Analysis of herpes zoster events among bortezomib-treated patients in the phase III APEX studyAsher Chanan-Khan, Pieter Sonneveld, Michael W Schuster, et al.
Blood Advances|November 12, 2021
MCT1 is a predictive marker for lenalidomide maintenance therapy in multiple myelomaJacob Stroh, Anja Seckinger, Michael Heider, et al.
Molecular Medicine (Cambridge, Mass.)|August 24, 2018
Enrichment of B cell receptor signaling and epidermal growth factor receptor pathways in monoclonal gammopathy of undetermined significance: a genome-wide genetic interaction studySubhayan Chattopadhyay, Hauke Thomsen, Miguel Inacio da Silva Filho, et al.
Pageof 54